GlycoMimetics' (GLYC) shares climbed by more than 125% early Tuesday after saying it has agreed to be acquired by Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics.
Under the deal, a syndicate of investors has committed $200 million to buy GlycoMimetics common stock and pre-funded warrants, the company said.
The transaction is expected to close in the second quarter of 2025, after which GlycoMimetics will operate under the name Crescent Biopharma, the company said.
GlycoMimetics stockholders are expected to own about 3.1% of the combined company, with the pre-acquisition Crescent shareholders owning the rest, GlycoMimetics said.
Price: 0.3842, Change: +0.22, Percent Change: +128.42
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。